Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion

Wang, Dong; Li, Yang; Yue, Dongli; Cao, Liu; Li, Lifeng; Wang, Dan; Yü, Ping; Shen, Zhibo; Yang, Zheng; Wang, Liping; Zhang, Yi

doi:10.1016/j.canlet.2019.03.040

Cited by 133 publications

(91 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with anti-TGF-β antibody restored the impaired T cell cytotoxic function in MPE. Furthermore, inhibiting TGF-β signaling in CD8 + T cells using dominant negative receptors can improve the function of exhausted cells (Wang et al, 2019b).…”

Section: Soluble Mediatorsmentioning

confidence: 99%

T Cell Dysfunction and Exhaustion in Cancer

Zhang

et al. 2020

Front. Cell Dev. Biol.

Self Cite

260

209

View full text Add to dashboard Cite

Tumor immunotherapy is a promising therapeutic strategy for patients with advanced cancers. T cells are key mediators of antitumor function that specifically recognize and react to tumor-expressing antigens and have proven critical for cancer immunotherapy. However, T cells are not as effective against cancer as expected. This is partly because T cells enter a dysfunctional or exhausted state, which is characterized by sustained expression of inhibitory receptors and a transcriptional state distinct from that of functional effector or memory T cells. T cell dysfunction induces the out of control of tumors. Recently, T cell dysfunction has been investigated in many experimental and clinical settings. The molecular definition of T cell dysfunction and the underlying causes of the T cell dysfunction has been advanced regardless of the fact that the pathways involved are not well elucidated, which proposing promising therapeutic opportunities in clinic. In this review, we will discuss the recent advances in the molecular mechanisms that affect TME and induce T cell dysfunction, and the development of promising immunotherapies to counteract the mechanisms of tumor-induced T cell dysfunction. Better understanding these underlying mechanisms may lead to new strategies to improve the clinical outcome of patients with cancer.

show abstract

Section: Soluble Mediatorsmentioning

confidence: 99%

T Cell Dysfunction and Exhaustion in Cancer

Zhang

et al. 2020

Front. Cell Dev. Biol.

Self Cite

260

209

View full text Add to dashboard Cite

show abstract

“…These molecular targets form the basis of several therapeutic HCC strategies currently being clinically developed to promote an effective anti-tumor immune response. Abbreviations: TAM, tumor-associated macrophages; Treg cells: regulatory T cells;VEGF, vascular endothelial growth factor and CCL22, which attract Tregs cells to cancer sites, thereby impeding cytotoxic T cell activation [23,24]. This may lead to a positive feedback loop between TAMs and Tregs, providing a new dimension to the immunosuppressive effects of cancer.…”

Section: Tumor-associated Macrophagesmentioning

confidence: 99%

Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities

et al. 2019

View full text Add to dashboard Cite

Incidence of hepatocellular carcinoma (HCC) is on the rise due to the prevalence of chronic hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues the mortality rate of HCC remains high. Immunotherapy is currently the new frontier of cancer treatment and the immunobiology of HCC is emerging as an area for further exploration. The tumor microenvironment coexists and interacts with various immune cells to sustain the growth of HCC. Thus, immunosuppressive cells play an important role in the anti-tumor immune response. This review will discuss the current concepts of immunosuppressive cells, including tumor-associated macrophages, marrow-derived suppressor cells, tumor-associated neutrophils, cancer-associated fibroblasts, and regulatory T cell interactions to actively promote tumorigenesis. It further elaborates on current treatment modalities and future areas of exploration.

show abstract

“…Moreover, TAMderived TGF-b in MPE can induce CCL22 expression through c-Fos, which promotes the recruitment of regulatory T cells (Treg). Then, the Treg secretes high levels of IL-8 to further induce TGF-b production from TAMs, thus which forms a vicious circle, and leads to the formation of an immunosuppressive microenvironment in MPE (127). Finally, in addition to the IFN-g mentioned above, TAMs promote the expression of PD-L1 in tumor cells by secreting IL-10 (128).…”

Section: Tams Promote Tumors Escape Immune Surveillancementioning

confidence: 99%

The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy

2020

View full text Add to dashboard Cite

Tumor microenvironment (TME) is composed of tumor cells and surrounding non-tumor stromal cells, mainly including tumor associated macrophages (TAMs), endothelial cells, and carcinoma-associated fibroblasts (CAFs). The TAMs are the major components of non-tumor stromal cells, and play an important role in promoting the occurrence and development of tumors. Macrophages originate from bone marrow hematopoietic stem cells and embryonic yolk sacs. There is close crosstalk between TAMs and tumor cells. With the occurrence of tumors, tumor cells secrete various chemokines to recruit monocytes to infiltrate tumor tissues and further promote their M2-type polarization. Importantly, M2-like TAMs can in turn accelerate tumor growth, promote tumor cell invasion and metastasis, and inhibit immune killing to promote tumor progression. Therefore, targeting TAMs in tumor tissues has become one of the principal strategies in current tumor immunotherapy. Current treatment strategies focus on reducing macrophage infiltration in tumor tissues and reprogramming TAMs to M1like to kill tumors. Although these treatments have had some success, their effects are still limited. This paper mainly summarized the recruitment and polarization of macrophages by tumors, the support of TAMs for the growth of tumors, and the research progress of TAMs targeting tumors, to provide new treatment strategies for tumor immunotherapy.

show abstract

Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion

Cited by 133 publications

References 34 publications

T Cell Dysfunction and Exhaustion in Cancer

T Cell Dysfunction and Exhaustion in Cancer

Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities

The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy

Contact Info

Product

Resources

About